PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'ISGlobal, Hospital Clínic - Universitat de Barcelona, Rosello 132, 5ª 2ª, 08036, Barcelona, Spain. carlos.chaccour@isglobal.org.\', \'Ifakara Health Institute, 67501, Ifakara, United Republic of Tanzania. carlos.chaccour@isglobal.org.\', \'Facultad de Medicina, Universidad de Navarra, 31008, Pamplona, Spain. carlos.chaccour@isglobal.org.\', \'Centro de Investigación Médica Aplicada, 31008, Pamplona, Spain.\', \'Clínica Universidad de Navarra, 31008, Pamplona, Spain.\', \'Facultad de Farmacia y Nutrición, Universidad de Navarra, 31008, Pamplona, Spain.\', \'Drug Development Unit Universidad de Navarra, 31008, Pamplona, Spain.\', \'ISGlobal, Hospital Clínic - Universitat de Barcelona, Rosello 132, 5ª 2ª, 08036, Barcelona, Spain.\', \'Departament de Fonaments Clínics, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.\', \'Department of General Internal Medicine, Clinical Pharmacology and Toxicology, Inselspital, Bern, University Hospital, 3010, Bern, Switzerland.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41598-020-74084-y
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 33051517
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
is ?:relation_isRelatedTo_publication of
?:title
  • Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all